Anixa Biosciences Stock In The News
| ANIX Stock | USD 3.14 0.16 4.85% |
Our overall analysis of Anixa Biosciences' news coverage and content from conventional and social sources shows investors' bearish mood towards Anixa Biosciences. The specific impact of Anixa Biosciences news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Anixa Biosciences' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Anixa Biosciences headlines in addition to utilizing other, more conventional financial analysis modules. Check out Anixa Biosciences Backtesting and Anixa Biosciences Hype Analysis. For more information on how to buy Anixa Stock please use our How to Invest in Anixa Biosciences guide.
Anixa |
Anixa Biosciences Today Top News and Investor Outlook
Anixa Biosciences Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Anixa and other traded companies coverage with news coverage. We help investors stay connected with Anixa headlines for the 2nd of December to make an informed investment decision based on correlating the impacts of news items on Anixa Stock performance. Please note that trading solely based on the Anixa Biosciences hype is not for everyone as timely availability and quick action are needed to avoid losses.
Anixa Biosciences stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Anixa earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Anixa Biosciences that are available to investors today. That information is available publicly through Anixa media outlets and privately through word of mouth or via Anixa internal channels. However, regardless of the origin, that massive amount of Anixa data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Anixa Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Anixa Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Anixa Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Anixa Biosciences alpha.
Anixa Largest EPS Surprises
Earnings surprises can significantly impact Anixa Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-03-12 | 2024-01-31 | -0.09 | -0.1 | -0.01 | 11 | ||
2023-09-06 | 2023-07-31 | -0.09 | -0.08 | 0.01 | 11 | ||
2021-01-07 | 2020-10-31 | -0.1 | -0.09 | 0.01 | 10 | ||
2021-06-10 | 2021-04-30 | -0.1 | -0.08 | 0.02 | 20 | ||
2021-03-11 | 2021-01-31 | -0.11 | -0.09 | 0.02 | 18 | ||
2020-09-08 | 2020-07-31 | -0.12 | -0.1 | 0.02 | 16 |
Anixa Biosciences Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Anixa Biosciences Stock. Current markets are slightly bearish. About 51% of major world exchanges and indexes are down. See today's market update for more information.
29th of November 2024
PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders Equity Non-Compli... at gurufocus.com
27th of November 2024
ADAG Stock Surges Amidst Biotech Sector Growth at gurufocus.com
25th of November 2024
IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Pr... at finance.yahoo.com
22nd of November 2024
Acquisition by Clay Siegall of 33943 shares of Immunome at 9.7787 subject to Rule 16b-3 at seekingalpha.com
21st of November 2024
Disposition of 19910 shares by Blume-jensen Peter of Acrivon Therapeutics, at 6.44 subject... at MacroaxisInsider
20th of November 2024
TFF Pharmaceuticals, Inc. Announces Chief Financial Officer Changes - Marketscreener.com at news.google.com
20th of November 2024
Anebulo Pharmaceuticals Advances Cannabis Toxicity Solutions - MSN at news.google.com
20th of November 2024
PMV Pharmaceuticals files 200M mixed securities shelf - TipRanks at news.google.com
19th of November 2024
An2 therapeutics CEO Eric Easom acquires 49,970 in stock at investing.com
18th of November 2024
Anixa Biosciences, Inc Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinic... at news.google.com
15th of November 2024
ARMISTICE CAPITAL, LLC Acquires Shares in TFF Pharmaceuticals Inc at gurufocus.com
15th of November 2024
Adagene shares downgraded to hold, target cut to 3.50 at investing.com
15th of November 2024
Disposition of 100 shares by Michelle Gilson of Arcellx at 95.0 subject to Rule 16b-3 at gurufocus.com
14th of November 2024
Cue BiopharmaAnnounces Strategic Organizational Transition at globenewswire.com
14th of November 2024
PolyPid Ltd. Q3 2024 Earnings Call Transcript at insidermonkey.com
14th of November 2024
Acrivon stock retains Outperform as BMO cuts target due to minor cash adjustments at investing.com
13th of November 2024
IN8bio stock target cut, analyst sustains buy rating on Q4 loss at investing.com
13th of November 2024
PolyPid Provides Corporate Update and Reports Third Quarter 2024 Financial Results at globenewswire.com
13th of November 2024
FMR LLCs Strategic Acquisition of Immunome Inc Shares at gurufocus.com
13th of November 2024
Acrivon Therapeutics GAAP EPS of -0.59 at seekingalpha.com
13th of November 2024
We Think Rezolute Needs To Drive Business Growth Carefully - Yahoo Finance at news.google.com
13th of November 2024
Michael Strahan responds to National Anthem backlash at newsweek.com
12th of November 2024
HC Wainwright Reaffirms Buy Rating for Annovis Bio at thelincolnianonline.com
11th of November 2024
Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate... at globenewswire.com
11th of November 2024
Disposition of 3005 shares by Patel Kavita of Arcellx at 106.9083 subject to Rule 16b-3 at MacroaxisInsider
7th of November 2024
PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference at finance.yahoo.com
7th of November 2024
Disposition of 8478 shares by Patel Kavita of Arcellx at 99.2995 subject to Rule 16b-3 at zacks.com
6th of November 2024
Disposition of 25482 shares by Rodman David Malcom of Mineralys Therapeutics, at 15.0328 s... at MacroaxisInsider
5th of November 2024
Arcellx Releases Clinical Data from Phase 1 and iMMagine-1 Studies for Multiple Myeloma Pa... at thelincolnianonline.com
1st of November 2024
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635 at businesswire.com
31st of October 2024
INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update at globenewswire.com
31st of October 2024
Shareholder Alert Ademi LLP Investigates Whether Aerovate Therapeutics, Inc. Is Obtaining ... at businesswire.com
30th of October 2024
Acquisition by Catelani Michael of 500000 shares of Anixa Biosciences subject to Rule 16b-... at MacroaxisInsider
25th of October 2024
Molecular Partners prices 20M offering at seekingalpha.com
23rd of October 2024
PMV Pharmaceuticals Provides a Progress Update on PYNNACLE Clinical Trial at finance.yahoo.com
22nd of October 2024
Disposition of 16000 shares by Titterton Lewis H Jr of Anixa Biosciences at 2.575 subject ... at Titterton Lewis H Jr
22nd of October 2024
Annovis to Highlight Buntanetaps Alzheimers Research Progress with Presentations at CTAD 2... at finance.yahoo.com
22nd of October 2024
Acquisition by English Aron R. of 714250 shares of Anebulo Pharmaceuticals at 7.0 subject ... at MacroaxisInsider
17th of October 2024
Anthem Blue Cross and Blue Shield Foundation and McShin Foundation Expand Support for Virg... at businesswire.com
16th of October 2024
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635 at globenewswire.com
15th of October 2024
Anixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Cl... at finance.yahoo.com
15th of October 2024
Acquisition by Rocamboli Stephen of 3165 shares of Tff Pharmaceuticals subject to Rule 16b... at MacroaxisInsider
14th of October 2024
Acquisition by Rodman David Malcom of 5352 shares of Mineralys Therapeutics, at 1.08 subje... at accesswire.com
9th of October 2024
Acquisition by Sandercock Colin of 100000 shares of Cue Biopharma at 3.21 subject to Rule ... at MacroaxisInsider
4th of October 2024
Annovis Bio Inc. Seeking to Strengthen Intellectual Property Portfolio, Protecting Multifa... at kalkinemedia.com
2nd of October 2024
Molecular Partners Stock Price Down 1.9 percent - Whats Next - MarketBeat at news.google.com
1st of October 2024
IN8bio dips 9, prices 12.4M private placement at seekingalpha.com
1st of October 2024
Heres Why Aerovate Therapeutics Must Use Its Cash Wisely - Simply Wall St at news.google.com
30th of September 2024
INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimers Disease at finance.yahoo.com
27th of September 2024
Anixa Biosciences Announces Submission of Protocol Amendment for CAR-T Trial - RTTNews at news.google.com
27th of September 2024
Cue Biopharma prices 12M stock offering at seekingalpha.com
27th of September 2024
Annovis Bio Progress With Buntanetap In Parkinsons Disease, But Cash Runway Concerns Loom ... at news.google.com
24th of September 2024
Acquisition by Hogenhuis Wladimir of 4259 shares of Rezolute at 4.7 subject to Rule 16b-3 at investing.com
20th of September 2024
HC Wainwright Analysts Lift Earnings Estimates for Adagene Inc. - MarketBeat at news.google.com
18th of September 2024
Anixa Biosciences, Inc. Expected to Post FY2024 Earnings of Per Share at thelincolnianonline.com
18th of September 2024
Disposition of 6387 shares by Gillies Hunter of Aerovate Therapeutics at 25.8137 subject t... at MacroaxisInsider
11th of September 2024
TFF Pharmaceuticals enters pact for dry powder mRNA-based Covid treatment at seekingalpha.com
9th of September 2024
FDA Gives Green Signal To Rezolutes Genetic Disorder Treatment at finance.yahoo.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Anixa Biosciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Anixa Biosciences' short interest history, or implied volatility extrapolated from Anixa Biosciences options trading.
Additional Tools for Anixa Stock Analysis
When running Anixa Biosciences' price analysis, check to measure Anixa Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Anixa Biosciences is operating at the current time. Most of Anixa Biosciences' value examination focuses on studying past and present price action to predict the probability of Anixa Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Anixa Biosciences' price. Additionally, you may evaluate how the addition of Anixa Biosciences to your portfolios can decrease your overall portfolio volatility.